Report period | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
SAVA:US | Cassava Sciences | Common share | - | US14817C1071 | $30.75 |
Company name | Cassava Sciences |
---|---|
Tags | #biotechnology |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 7801 North Capital of Texas Highway Suite 260 Austin, TX 78731 United States |
Mailing address | 7801 North Capital of Texas Highway Suite 260 Austin, TX 78731 United States |
Website | www.cassavasciences.com |